Treatment of Chronic Mountain Sickness
Launched by CENTRE D'EXPERTISE SUR L'ALTITUDE EXALT · Jan 30, 2020
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
About 100 million individuals reside at high altitude (\>2500m) worldwide, with the largest populations of highlanders being found in South America (Andean), central Asia (Tibetan and Sherpa) and East Africa (Ethiopian). Despite unique adaptations to hypoxia in these populations, chronic mountain sickness (CMS) is a clinical syndrome which is observed in 5-33% of individuals residing permanently at high altitude.Several pharmacological approaches have been proposed in the treatment of EE and CMS. However, few studies show sufficient clinical evidence for safety and efficacy in CMS treatment...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male
- • Age between 18 and 55 yrs
- • Body mass index \<30kg/m²
- • Born at \>3500 m, living for \>3 years at the local high altitude
- • No diagnosis of cardiorespiratory, metabolic or neurological diseases
- • No drug intake
- • No smoker
- • Chronic mountain sickness score ≥6
- Exclusion Criteria:
- • Diagnosis of cardiorespiratory, metabolic and neurological diseases
- • Systolic \> 130 mmHg and/or diastolic \> 85 mmHg blood pressure
- • Drug intake
- • Smoker
- • Chronic mountain sickness score \<6
About Centre D'expertise Sur L'altitude Exalt
The Centre d'Expertise sur l'Altitude Exalt is a leading clinical trial sponsor dedicated to advancing research in high-altitude physiology and its impacts on human health. With a focus on innovative studies that explore the effects of altitude on physical performance, acclimatization, and related health outcomes, the center collaborates with top-tier academic institutions and healthcare professionals. Committed to rigorous scientific methodologies and ethical standards, Exalt aims to contribute valuable insights that enhance our understanding of altitude-related challenges and improve strategies for health and performance in extreme environments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
échirolles, , France
Patients applied
Trial Officials
Samuel Verges, PhD
Principal Investigator
EXAL
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials